Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

Abstract: The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Abstract: The present invention relates to a tosylate salt of Compound 1 and polymorphs thereof, in particular crystalline and amorphous forms of Compound 1 tosylate salt, and methods of preparation thereof. Pharmaceutical compositions containing these salts as active ingredient, their use in the manufacture of medicaments for use in the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body, and their use in methods for the treatment and/or prophylaxis of proliferative disease states, such as cancer, in the human or animal body are also described.

Abstract: The present invention relates to a ZD6474 monohydrate, to processes for the preparation of a ZD6474 monohydrate, to pharmaceutical compositions comprising a ZD6474 monohydrate as the active ingredient, to the use of a ZD6474 monohydrate in the manufacture of medicaments for use in the production of antiangiogenic and/or vascular permeability reducing effects in warm-blooded animals such as humans, and to the use of a ZD6474 monohydrate in methods for the treatment of disease states associated with angiogenesis and/or increased vascular permeability, such as cancer, in warm-blooded animals such as humans.

Abstract: Disclosed are MEK inhibitors useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

Abstract: In a workload managed system comprising a plurality of server processes each capable of supporting a given program entity, such as an Enterprise JavaBeans™ specified stateful session bean, a stateful session bean instance is passivated, by writing it to a bean store, on completion of a unit of work. On next use the session bean is reactivated, by reading it from the bean store, in any one of the plurality of servers thereby allowing workload management for stateful session beans. A routing table is maintained, in non-volatile mass storage, that contains location information for units of work and stateful session bean instances, used to maintain unit of work-server affinity for the lifetime of the unit of work Stateful session beans instances are associated with ID keys that include a flag that is used to indicate whether or not the routing table contains location information for the bean instance.

Abstract: The present invention relates to the field of diagnostic imaging. Specifically, the invention relates to the diagnostic imaging of diseases where specific matrix metalloproteinases are known to be involved. One embodiment of the invention is a compound having matrix metalloproteinase inhibitory activity suitable for diagnostic imaging. Also disclosed in the present invention is a pharmaceutical composition comprising the diagnostic imaging agent of the invention in a form suitable for mammalian administration. The invention furthermore discloses intermediates in the synthesis of the diagnostic imaging agents of the invention and kits for the preparation of the pharmaceutical composition of the invention. The pharmaceutical composition of the invention may be used in the diagnosis of diseases where specific matrix metalloproteinases are known to be involved.

Abstract: Synthetic analogues of lysine and glutamine are provided which function as substrates for the fibrin-stabilising enzyme Factor XIIIa even when labelled with a detectable moiety. The use of suitable protecting groups provides compounds which possess reduced susceptibility to in vivo metabolism especially by peptidases, and are hence useful agents for the diagnosis of thrombosis, embolism, atherosclerosis, inflammation or cancer.

Abstract: The present invention provides an improved process for the preparation of a polymorph of eletriptan hemisulphate.

Abstract: A peptide-chelate with affinity for the ST receptor is disclosed, wherein the chelate is tetradentate. The peptide-chelate conjugate of the invention may be labelled with a radiometal to provide a metal complex. A radiopharmaccutical composition comprising the metal complex is provided, which is suitable for the diagnostic imaging of colorectal cancer. Also provided for in the invention is a kit for the preparation of the radiopharmaceutical preparation.

Abstract: The present invention provides an improved stabiliser for radiopharmaceuticals which inhibits impurities from being produced by two kinds of decomposition mechanisms and exhibits such an effect that the shelf life of a radiopharmaceutical after its preparation is prolonged as compared with conventional ones. The improvement comprises a combination of an amino-substituted aromatic carboxylic acid or its salt, ester or amide in combination with a diphosphonic acid or its salt.

Abstract: The present invention provides a more flexible version of an EJB container which permits easy definition an EJB component which observes a behavior pattern which is not typical of a session, entity or message driven bean types. In this flexible EJB container, behavior characteristics normally fixed by the bean type of the EJB component, such as passivation policy, usage, recoverability, and relocatability can be separately defined for each EJB component.

Abstract: A novel solid form of sildenafil citrate wherein the ratio of sildenafil: citrate is 1:0.5.

Abstract: In a workload managed system comprising a plurality of server processes each capable of supporting a given program entity, such as an Enterprise JavaBeans™ specified stateful session bean, a stateful session bean instance is passivated, by writing it to a bean store, on completion of a unit of work. On next use the session bean is reactivated, by reading it from the bean store, in any one of the plurality of servers thereby allowing workload management for stateful session beans. A routing table is maintained, in non-volatile mass storage, that contains location information for units of work and stateful session bean instances, used to maintain unit of work-server affinity for the lifetime of the unit of work Stateful session beans instances are associated with ID keys that include a flag that is used to indicate whether or not the routing table contains location information for the bean instance.